(2R,3S,4S,5S)-2-[5,6-dichloro-2-(propan-2-ylamino)benzimidazol-1-yl]-5-(hydroxymethyl)oxolane-3,4-diol

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 苯并咪唑核糖核苷和核糖核苷酸
• 英文名称: (2R,3S,4S,5S)-2-[5,6-dichloro-2-(propan-2-ylamino)benzimidazol-1-yl]-5-(hydroxymethyl)oxolane-3,4-diol
• 化学式: C₁₅H₁₉Cl₂N₃O₄
• 分子量: 376.2
• InChiKey: KJFBVJALEQWJBS-RFQIPJPRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  99.8
• 氢给体数：
  4
• 氢受体数：
  6

文献信息

• Maribavir isomers, compositions, methods of making and methods of using
  申请人：Shire ViroPharma Incorporated

  公开号：US10485813B2

  公开（公告）日：2019-11-26

  The invention relates to novel compositions and methods of using maribavir which enhance its effectiveness in medical therapy, as well as to maribavir isomers and methods of use thereof for counteracting the potentially adverse effects of maribavir isomerization in vivo in the event it occurs.

  本发明涉及新型组合物和使用马立巴韦的方法，这些组合物和方法可提高马立巴韦在医学治疗中的有效性，本发明还涉及马立巴韦异构体及其使用方法，这些异构体可在体内发生马立巴韦异构化时抵消其潜在的不利影响。
• MARIBAVIR ISOMERS, COMPOSITIONS, METHODS OF MAKING AND METHODS OF USING
  申请人：Peabody John D.

  公开号：US20120283210A1

  公开（公告）日：2012-11-08

  The invention relates to novel compositions and methods of using maribavir which enhance its effectiveness in medical therapy, as well as to maribavir isomers and methods of use thereof for counteracting the potentially adverse effects of maribavir isomerization in vivo in the event it occurs.
• US8940707B2
  申请人：——

  公开号：US8940707B2

  公开（公告）日：2015-01-27